AimGelTM: unleashing the power of artificial cells for cell and gene therapy.

Allegrow Biotech is a Hong Kong-based biotech startup, spin-off from Hong Kong University of Science and Technology. The company’s vision is to bring cell therapy to all by offering platform and solutions to accelerate cell cultivation and clinical translation. Our proprietary platform technology, AimGelTM is a hydrogel microparticle, poised to mimic feeder cells to deliver necessary growth factors and membrane signals to enable and expedite cell growth on dish, prior to patient administration.

AimGel is designed to replace feeder cells to reduce the multi-step cell manufacturing steps while assuring good cell quality and reproducibility. AimGel’s modular structure combines with Quality by Design (QbD) of cell manufacturing process optimization to further increase the cost-effectiveness and customizability in growing diverse cell therapeutics. Our MVP Aim-TconvTM targets the CAR-T market led by the giant pharma and is now under in-house validation by several biotech companies and research institutes worldwide. Established in March 2022, the company has filed 3 patents, 15+ publications and conferences and 9+ awards. The company also recently won the Grand Prize of Alibaba Entrepreneurs Fund Jumpstarter 2023.

Join our December meetup to discuss how technology innovates to solve medical challenges.

Send RSVP -training@bluechiptraining.biz